ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2550

Clinical, Radiographic, and Immunogenic Effects After 1 Year of Tocilizumab-Based Treatment Strategy with and without Methotrexate in Rheumatoid Arthritis: The ACT-RAY Study

Maxime Dougados1, Karsten Kissel2, Philip G. Conaghan3, Emilio Martin-Mola4, Georg A. Schett5, Howard Amital6, Ricardo M. Xavier7, OM Troum8, Corrado Bernasconi9 and T.W.J. Huizinga10, 1Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 2F. Hoffmann-La Roche Ltd, Basel, Switzerland, 3University of Leeds, Leeds, United Kingdom, 4Rheumatology, Hospital Universitario La Paz, Madrid, Spain, 5Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 6Sheba Medical Center, Tel-Hashomer, Israel, 7Rheumatology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, 8Medicine, USC Keck School of Medicine, Santa Monica, CA, 9Consultant, Basel, Switzerland, 10Rheumatology, Leiden University Medical Center, Leiden, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Multicenter study, rheumatoid arthritis (RA) and tocilizumab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics

Session Type: Abstract Submissions (ACR)

Background/Purpose: 24-week data from ACT-RAY comparing an add-on strategy (tocilizumab [TCZ] + methotrexate [MTX]) with a switch strategy (TCZ + placebo [PBO]) in MTX-IR patients have been previously reported, demonstrating relevant clinical and radiographic benefit without a statistically significant difference between the 2 groups for most endpoints. Longer-term data are needed to assess the switch and add-on strategies over time and the effect of the protocol-specified treat-to-target strategy in patients who started on TCZ monotherapy or combination with MTX after Week 24. Therefore, the objective here is to assess the 52 week efficacy and safety of a TCZ-based treat-to-target strategy in patients who started treatment with and without MTX in adult patients with moderate to severe RA and an inadequate response to MTX.

Methods: ACT-RAY is a phase 3b clinical trial. Patients on stable doses of MTX were randomized to either add TCZ 8 mg/kg IV every 4 weeks to their existing MTX (add-on group) or switch to TCZ 8 mg/kg IV every 4 weeks with oral PBO (switch group). The protocol instituted the addition of open-label conventional DMARDs other than MTX at Week 24 or later in patients with DAS28 > 3.2, maintaining the blinding of MTX/PBO. 

Results: 556 patients were randomized, with 85% completing 52 weeks of treatment. Baseline data were similar between the 2 groups (disease duration 8.2 yrs, DAS28-ESR 6.3, HAQ-DI 1.47 [all mean values]) except for Genant-modified Sharp Score (GSS), which was higher in the switch group. Efficacy results are shown in the table. Between Weeks 24 and 52, the proportion of patients receiving DMARD intensification was comparable in the add-on and switch arms (29% vs 33%). Clinical improvements at Week 24 in both groups were maintained or further improved up to Week 52 with a trend in favor of the add-on strategy for some endpoints. While the vast majority of patients did not experience a change from baseline, significantly more switch patients experienced radiographic progression (14.5% versus 7.6% in the add-on group). In a preliminary analysis in patients with samples available, 3.7% of patients developed antidrug antibodies (ADAs) up to week 52: 10/272 in the add-on group and 11/271 in the switch group. Neutralizing ADAs were developed by 3.3% of patients (9/272) in the add-on group and 4.1% (11/271) in the switch group.  Rates of SAEs and serious infections per 100 PY were 14.2 and 4.9 in the add-on group and 17.7 and 6.3 in the switch group, respectively. In patients with normal baseline values, ALT elevations >3x the upper limit of normal were observed in 11% of add-on and 3% of switch patients.

Conclusion: This one year analysis suggests that TCZ monotherapy might be an acceptable therapeutic strategy in patients with a contraindication for or intolerance to MTX.

 

Table: Week 24 and 52 Efficacy Results (ITT Population)

Clinical Parameter

Week 24

Week 52

Add-on
n = 277

Switch
n = 276

P value

Add-on
n = 277

Switch
n = 276

P value

DAS28, mean change from baseline

-3.43

-3.21

0.06a

-3.74

-3.66

0.67a

DAS28 remission
(DAS28 <2.6), %

40.4

34.8

0.21

45.5

36.6

0.03

Low disease activity
(DAS28 ≤3.2), %

61.7

51.4

0.031

62.5

57.2

0.12

ACR20/50/70/90,%

71.5/45.5/
24.5/5.8

70.3/40.2/
25.4/5.1

0.87/0.30/
0.68/0.84

70.8/50.2/
31.4/12.6

69.2/55.4/
31.2/11.2

0.62/0.22/
0.99/0.65

SJC (66)/TJC (68), mean change from baseline

−11.3/
−17.3

−11.8/
−17.0

0.8/0.9

−12.3/
−19.4

−12.2/
−18.9

0.9/0.7

GSS, mean change from baseline

0.27

0.40

0.33b

0.40

0.63

0.44b

Patients w/o radiographic progression,c %

90.6

87.3

0.18

92.4

85.5

0.007

 a P values adjusted for baseline DAS28 and region.

 b Estimates and Pvalues adjusted for baseline DAS28 and baseline GSS.

 c No progression defined as GSS of ≤ 1.5 (SDC) (patients with missing observations classified as progressors). Not adjusted by GSS at baseline.


Disclosure:

M. Dougados,

Pfizer Inc,

2,

Pfizer Inc,

6,

Pfizer Inc,

5,

Roche Pharmaceuticals,

2,

Roche Pharmaceuticals,

6,

Abbott Immunology Pharmaceuticals,

2,

Abbott Immunology Pharmaceuticals,

6,

UCB,

2,

Ucb,

6,

ucb,

5,

Roche Pharmaceuticals,

5,

Abbott Immunology Pharmaceuticals,

5;

K. Kissel,

F. Hoffmann-La Roche Ltd.,

3;

P. G. Conaghan,

Centocor, Inc., Roche,

2,

Astra Zeneca, Bioberica, BMS, Centocor, Merck, Novartis, Pfizer, Roche,

8;

E. Martin-Mola,

Abbott Immunology, Roche, Pfizer, UCB,

5;

G. A. Schett,

Roche,

5;

H. Amital,
None;

R. M. Xavier,

Pfizer Inc,

5,

Pfizer, Roche, Merck,

8;

O. Troum,

Genentech,

2,

Genentech,

5;

C. Bernasconi,

Roche Pharmaceuticals,

3;

T. W. J. Huizinga,

Abbott Immunology, Axis Shield Diagnostics, Biotest AG, BMS, Crescendo Bioscience, Roche, Novartis, Schering-Plough, UCB, Wyeth-Pfizer,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-radiographic-and-immunogenic-effects-after-1-year-of-tocilizumab-based-treatment-strategy-with-and-without-methotrexate-in-rheumatoid-arthritis-the-act-ray-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology